# A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants

> **NCT05338489** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Selpercatinib
- **DRUG:** Itraconazole
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT05338489
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-11
- **Primary completion:** 2018-07-28
- **Final completion:** 2018-08-22
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05338489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05338489, "A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05338489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*